A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Pediatric Blood & Cancer

• Publication date

  2008-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pbc.21132PMID 17262795
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.

  2005cited by this paper
• Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein: A phase II clinical trial

  2005cited by this paper
• A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

  2005cited by this paper
• Pleural‐pericardic effusion as uncommon complication in CML patients treated with Imatinib

  2005cited by this paper
• Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein

  2005cited by this paper
• Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

  2005cited by this paper
• PDGF-A, PDGF-Rβ, TGFβ3 and bone morphogenic protein-4 in desmoplastic small round cell tumors with EWS-WT1 gene fusion product and their role in stromal desmoplasia: an immunohistochemical study

  2005cited by this paper
• Lack of clinical efficacy of imatinib in metastatic melanoma

  2005cited by this paper
• A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer

  2005cited by this paper
• Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

  2005cited by this paper
• Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates

  2004cited by this paper
• Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis

  2004cited by this paper
• Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.

  2004cited by this paper
• The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

  2004cited by this paper
• Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.

  2004cited by this paper
• The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management

  2004cited by this paper
• Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor β Tyrosine Kinase Receptors in Synovial Sarcoma

  2004cited by this paper
• Book Review

  2003cited by this paper
• Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

  2003cited by this paper
• Double target for tumor mass destruction.

  2003cited by this paper
• Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.

  2003cited by this paper
• Phase II study of imatinib in patients with small cell lung cancer.

  2003cited by this paper
• Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

  2002cited by this paper
• c-kit Expression in Pediatric Solid Tumors: A Comparative Immunohistochemical Study

  2002cited by this paper
• Unexpected pleural effusions in 3 pediatric patients treated with STI-571.

  2002cited by this paper
• Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

  2000cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000cited by this paper
• Platelet-Derived Growth Factor-AA and -α Receptor Expression Suggests an Autocrine and/or Paracrine Loop in Osteosarcoma

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Effects of human platelet-derived growth factor-AB on sarcoma growth in vitro and in vivo.

  1999cited by this paper
• Intra-abdominal desmoplastic small round cell tumor: immunohistochemical evidence for up-regulation of autocrine and paracrine growth factors.

  1999cited by this paper
• The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour

  1997cited by this paper
• Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression.

  1995cited by this paper
• Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group

  1994cited by this paper
• Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group.

  1994cited by this paper
• Platelet-derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors.

  1992cited by this paper

• Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors.

  2026cites this paper
• Tyrosine kinase inhibitors in Ewing’s sarcoma: a systematic review

  2025cites this paper
• Cation-free siRNA micelle knockdown of EPHA2 improves sensitivity of imatinib for osteosarcoma treatment

  2025cites this paper
• Anticancer therapy-induced adverse drug reactions in children and preventive and control measures

  2024cites this paper
• Signaling pathways and targeted therapies in Ewing sarcoma.

  2024cites this paper
• Genetic and molecular profiling in bone sarcomas: advancing personalized treatment approaches

  2024cites this paper
• Osteosarcoma: A comprehensive review of model systems and experimental therapies

  2024cites this paper
• Analysis of cancer multigene panel testing for osteosarcoma in pediatric and adults using the center for cancer genomics and advanced therapeutics database in Japan.

  2024cites this paper
• Outcome of patients with relapsed or refractory nonrhabdomyosarcoma soft tissue sarcomas enrolled in phase 2 cooperative group clinical trials: A report from the Children’s Oncology Group

  2024cites this paper
• Hypoxia and HIFs in Ewing sarcoma: new perspectives on a multi-facetted relationship

  2023cites this paper
• Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa

  2023cites this paper
• Saquinavir: From HIV to COVID-19 and Cancer Treatment

  2022cites this paper
• Tyrosine kinase inhibitors in sarcoma treatment

  2022cites this paper
• Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults

  2022cites this paper
• Practical Recommendations for the Manipulation of Kinase Inhibitor Formulations to Age-Appropriate Dosage Forms

  2022cites this paper
• Origin and Therapies of Osteosarcoma

  2022cites this paper
• Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality

  2022cites this paper
• Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

  2021cites this paper
• RNA sequencing and functional studies of patient-derived cells reveal that neurexin-1 and regulators of this pathway are associated with poor outcomes in Ewing sarcoma

  2021cites this paper
• Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives

  2021cites this paper
• Targeted therapy in metastatic, recurrent and refractory Ewing sarcoma and osteogenic sarcoma. Review of literature

  2021cites this paper
• Comparative characteristics of small cell lung cancer and Ewing’s sarcoma: a narrative review

  2021cites this paper
• Systematic Review of Recurrent Osteosarcoma Systemic Therapy

  2021cites this paper
• Synovial sarcoma of the stomach: a case report and a systematic review of literature

  2021cites this paper
• Novel 2-phenyl-3-(Pyridin-2-yl) thiazolidin-4-one derivatives as potent inhibitors for proliferation of osteosarcoma cells in vitro and in vivo.

  2021cites this paper
• The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?

  2021cites this paper
• Use of Antiangiogenic Therapies in Pediatric Solid Tumors

  2021influential citation
• Intra-Abdominal Desmoplastic Small Round Cell Tumor: Current Treatment Options and Perspectives

  2021cites this paper
• Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor

  2021cites this paper
• Intraabdominal and ganglionic desmoplastic small round cell tumor: a case series

  2021cites this paper
• Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors

  2021cites this paper
• Mini-Review on Targeted Treatment of Desmoplastic Small Round Cell Tumor

  2020cites this paper
• Receptor Tyrosine Kinases in Osteosarcoma: 2019 Update.

  2020cites this paper
• TAS‐115 inhibits PDGFRα/AXL/FLT‐3 signaling and suppresses lung metastasis of osteosarcoma

  2020cites this paper
• A 3D-printed biomaterials-based platform to advance established therapy avenues against primary bone cancers.

  2020cites this paper
• Desmoplastic Small Round Cell Tumor: A Review of Main Molecular Abnormalities and Emerging Therapy

  2020cites this paper
• Role of TKI for Metastatic Osteogenic Sarcoma

  2020cites this paper
• Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

  2020cites this paper
• Current Treatment Considerations for Osteosarcoma Metastatic at Presentation.

  2020cites this paper
• Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma

  2020cites this paper
• Management of recurrent or refractory Ewing sarcoma: A systematic review of phase II clinical trials in the last 15 years.

  2019cites this paper
• Low-Dose Radiation Prevents Chemotherapy-Induced Cardiotoxicity

  2019cites this paper
• Medicine and Pharmacy

  2019cites this paper
• Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma

  2019cites this paper
• Biomechanical regulation of drug sensitivity in an engineered model of human tumor.

  2018cites this paper
• Involvement of platelet‐derived growth factor ligands and receptors in tumorigenesis

  2018cites this paper
• Advances in chromosomal translocations and fusion genes in sarcomas and potential therapeutic applications.

  2018cites this paper
• Gastrointestinal Stromal Tumors.

  2018cites this paper
• Tailored approaches to rare sarcomas: current challenges and future prospects

  2018influential citation
• PDGF/PDGFR effects in osteosarcoma and the “add-on” strategy

  2018cites this paper
• Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression.

  2018cites this paper
• Sequential use of second‐generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group

  2018cites this paper
• [Desmoplastic small round cell tumor in children, adolescents and young adults].

  2018cites this paper
• Multidisciplinary sarcoma care.

  2018cites this paper
• Pharmacology and pharmacokinetics of imatinib in pediatric patients

  2018influential citation
• Trabectedin in advanced desmoplastic round cell tumors: a retrospective single-center series

  2017cites this paper
• Involvement of PDGF ligands and receptors in tumorigenesis

  2017cites this paper
• Synovial Sarcoma: Advances in Diagnosis and Treatment Identification of New Biologic Targets to Improve Multimodal Therapy

  2017cites this paper
• Imatinib mesylate in desmoplastic small round cell tumors.

  2017cites this paper
• Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies

  2017cites this paper
• Investigational drugs in phase II clinical trials for the treatment of neuroblastoma

  2017cites this paper
• In Vitro Sensitivity Profiling of Neuroblastoma Cells Against A Comprehensive Small Molecule Kinase Inhibitor Library to Identify Agents for Future Therapeutic Studies.

  2017cites this paper
• Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single‐center experience

  2017cites this paper
• Exploring targeted therapy of osteosarcoma using proteomics data

  2017cites this paper
• Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma

  2016cites this paper
• Investigational therapies for Ewing sarcoma: a search without a clear finding

  2016influential citation
• Desmoplastic Small Round Cell Tumor

  2016cites this paper
• Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines

  2016cites this paper
• Drugs in early clinical development for the treatment of osteosarcoma

  2016cites this paper
• Potential approaches to the treatment of Ewing's sarcoma

  2016cites this paper
• Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.

  2016cites this paper
• Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers

  2016cites this paper
• Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers

  2015cites this paper
• Abdominal monophasic synovial sarcoma is a morphological and immunohistochemical mimic of gastrointestinal stromal tumour

  2015cites this paper
• PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1

  2015cites this paper
• Improving access to novel agents for childhood leukemia

  2015cites this paper
• Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study.

  2015cites this paper
• Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.

  2015cites this paper
• Desmoplastic small round cell tumor 20 years after its discovery.

  2015cites this paper
• Pericytes in sarcomas of bone

  2015cites this paper
• Ewing Sarcoma: Focus on Medical Management

  2015cites this paper
• Targeted therapies for advanced Ewing sarcoma family of tumors.

  2015influential citation
• Cardiovascular disease in adult survivors of childhood cancer.

  2015cites this paper
• Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis

  2015cites this paper
• EWS-FLI1 Regulates Genotoxic Stress Response in Ewing

  2015cites this paper
• Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy

  2015cites this paper
• Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells

  2015cites this paper
• Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization

  2015cites this paper
• Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute

  2014cites this paper
• Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models

  2014cites this paper
• Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.

  2014cites this paper
• Ewing's sarcoma of bone.

  2014cites this paper
• Appropriate Modulation of Autophagy Sensitizes Malignant Peripheral Nerve Sheath Tumor Cells to Treatment With Imatinib Mesylate

  2014cites this paper
• Managing children with chronic myeloid leukaemia (CML)

  2014cites this paper
• Advances in Therapy for Pediatric Sarcomas

  2014cites this paper
• Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience

  2014cites this paper
• Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers

  2014cites this paper
• Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy

  2014cites this paper
• Molecular profiling of childhood cancer: Biomarkers and novel therapies

  2014cites this paper
• Targeting the PDGF signaling pathway in tumor treatment

  2013cites this paper